Riskpilot← Back to searchSign inGet full accessDania Therapeutics ApS
APSActiveCVR 42523925Store Kongensgade 77Research and experimental development on natural sciences and engineering · NACE 7210Est. 20211 employees
Revenue 2024
DKK 0
EBITDA margin
—
+1% vs 2023
Equity ratio
-145.4%
Financial strength
Net profit 2024
DKK -9,6M
-10% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK -10,3M | +1% |
| Net profit | DKK -9,6M | -10% |
| Total assets | DKK 7,1M | -53% |
| Equity | DKK -10,4M | -746% |
| Employees | 1 | — |
Legal name
Dania Therapeutics ApS
CVR number
42523925
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1. juli 2021
Share capital
DKK 59.711
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er at drive forsknings- og udviklingsvirksomhed inden for bioteknologi med henblik på udvikling og kommercialisering af lægemidler inden for cancer samt anden i forbindelse hermed stående virksomhed
Address
Store Kongensgade 77
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Staff expenses | -0 | -1.240 | -1.480 |
| EBITDA | -12.859 | -10.431 | -10.317 |
| Depreciation & amort. | -0 | -0 | -0 |
| EBIT | -12.859 | -10.431 | -10.317 |
| Net financials | 298 | -291 | -1.137 |
| Profit before tax | -12.561 | -10.722 | -11.454 |
| Tax | -2.820 | -2.000 | -1.897 |
| Net profit | -9.741 | -8.722 | -9.557 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 2.990 | 15.063 | 7.136 |
| Equity | 2.826 | -1.227 | -10.373 |
| Long-term debt | 100 | 15.611 | 16.754 |
| Short-term debt | 64 | 679 | 755 |
| Total debt | 164 | 16.290 | 17.510 |
EBITDA margin
-1031665400.0%
This company
15.8%
Market median
-6529527948% vs market
20222024
Equity ratio
-145.4%
This company
38.2%
Market median
-481% vs market
20222024
Return on equity
-955685500.0%
This company
18.4%
Market median
-5193943035% vs market
20222024
Net profit margin
-955685500.0%
This company
8.1%
Market median
-11798586520% vs market
20222024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20222024
Debt / equity
1.69×
This company
0.62×
Market median
-173% vs market
20222024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HM Management | Management | 2021 | — | — |
KA Founder | Founder | 2021 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2021 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 33.3% | 33.3% | 2022 | |
| Individual | 25.0% | 25.0% | 2022 | |
Hannibal Innovation ApS | Company | 15.0% | 15.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dania Therapeutics ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hamed Mozaffari Brodersen | Management | 0 companies |
| Karl Agger | Founder | 0 companies |
| Kim Andersen | Board of Directors | 0 companies |
| Lars Michael Wood | Board of Directors | 0 companies |
| Michael Manchuan Li | Board of Directors | 0 companies |
| Karin Absalonsen | Chairman | 0 companies |